封面
市场调查报告书
商品编码
1600972

感染疾病体外诊断市场:按产品、技术、适应症和最终用户划分 - 2025-2030 年全球预测

Infectious Diseases In-Vitro Diagnostics Market by Product (Instruments, Reagents, Software), Technology (Immunochemistry, Microbiology, Molecular Diagnostics), Indication, End-user - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年,感染疾病体外诊断市值为490.6亿美元,预计到2024年将达到525.1亿美元,复合年增长率为7.22%,到2030年将达到799.5亿美元。

感染疾病体外诊断(IVD)市场范围包括对血液、组织和其他体液等样本进行诊断测试,以检测人体内的感染疾病。由于全球感染疾病爆发次数不断增加、对快速诊断解决方案的需求不断增加以及 COVID-19 等流行病的持续威胁,该市场变得至关重要。这些诊断对于及时、准确的诊断、促进适当的治疗计划和管理、从而挽救生命和减少疾病传播至关重要。最终用途包括检测爱滋病毒、流感、结核病、肝炎、新兴感染疾病等,并包括医院、临床实验室和照护现场。市场成长受到次世代定序、PCR 和免疫测量等技术进步的显着影响,这些技术进步提高了准确性和速度。利用人工智慧和机器学习来解释诊断结果的新颖用途也带来了显着的机会。此外,在便利性、结果即时解释和隐私的推动下,人们对家庭测试的日益重视,正在该行业中开闢出一个重要的利基市场。然而,先进诊断技术的高价格、监管障碍以及新兴市场有限的医疗基础设施等挑战正在限制市场扩张。由于某些测试中的技术限製而导致的不可靠结果也可能成为阻碍力。技术创新的关键领域是开发价格实惠、简单且高度灵敏的携带式诊断仪。此类创新可以大大提高可及性,尤其是在世界资源匮乏的环境中。此外,寻找新疾病的生物标记以及同时针对多种病原体的多重测试的扩展可能会改变游戏规则。随着新的传染性威胁的频繁出现,这个市场的性质是高度动态的,需要技术提供者和医疗保健专业人员之间持续的研究和开发投资以及合作,以保持熟练的应对力。利用市场机会的建议包括策略伙伴关係和对研发的大力投资,以开发更有效、更便宜的诊断方法。

主要市场统计
基准年[2023] 490.6亿美元
预测年份 [2024] 525.1亿美元
预测年份 [2030] 799.5亿美元
复合年增长率(%) 7.22%

市场动态:快速发展的感染疾病体外诊断市场的关键市场洞察

感染疾病体外诊断市场正因供需之间的动态互动而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险,同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 感染疾病流行不断增加和週期性爆发
    • 更多采用快速检测套组进行感染疾病诊断
    • 实施政府倡议抑制病毒性疾病
  • 市场限制因素
    • 召回感染疾病体外诊断药物
  • 市场机会
    • 基因组学和蛋白​​质组学的进展
    • 增加研发投资推出新的体外诊断
  • 市场挑战
    • 感染疾病体外诊断试剂套件的供应有限

波特五力:引领感染疾病体外诊断市场的策略工具

波特的五力架构是了解感染疾病体外诊断市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势,解决弱点并避免潜在的挑战,从而确保更强大的市场地位。

PESTLE分析:了解外部对感染疾病体外诊断市场的影响

外部宏观环境因素在塑造感染疾病体外诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素,公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化,并为他们做出积极主动的决策做好准备。

市场占有率分析 了解感染疾病体外诊断市场的竞争状况

对感染疾病体外诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势,为供应商提供了製定策略决策所需的洞察力,使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵感染疾病体外诊断市场供应商绩效评估

FPNV定位矩阵是评估感染疾病体外诊断市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商,从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商,帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析:

1. 市场渗透率:对当前市场环境的详细回顾,包括行业主要企业的大量资料。

2. 市场开拓:辨识新兴市场的成长机会,评估现有领域的扩张潜力,并提供未来成长的策略蓝图。

3. 市场多元化:分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报:彻底分析竞争格局,检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新:重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题,以帮助相关人员做出明智的决策:

1.目前的市场规模和未来的成长预测是多少?

2. 哪些产品、区隔市场和地区提供最佳投资机会?

3.塑造市场的主要技术趋势和监管影响是什么?

4.主要厂商的市场占有率和竞争地位如何?

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么?

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病和週期性流行病的传播增加
      • 增加引进用于诊断感染疾病的快速检测套组
      • 实施政府控制病毒性疾病的倡议
    • 抑制因素
      • 召回感染疾病体外诊断产品
    • 机会
      • 基因组学和蛋白​​质组学的进展
      • 加大研发投入,推出新的IVD产品
    • 任务
      • 感染疾病体外诊断试剂套件准入限制
  • 市场区隔分析
    • 产品:对检测传染性病原体的先进试剂的需求不断增长
    • 技术:扩大分子诊断技术的采用,以快速检测和量化爱滋病毒和肝炎感染等病毒量
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章感染疾病体外诊断市场:副产品

  • 装置
  • 试剂
  • 软体

第七章感染疾病体外诊断市场:依技术分类

  • 免疫化学
  • 微生物学
  • 分子诊断

第八章感染疾病体外诊断市场(依适应症)

  • 念珠菌症
  • 披衣菌感染
  • 困难梭状芽孢桿菌
  • 创新的
  • 胃肠炎
  • 淋病
  • 肝炎
  • HIV
  • HPV
  • MRSA
  • 呼吸道病毒
  • 链球菌
  • 结核病和抗药性结核病
  • VRE

第九章感染疾病体外诊断市场:依最终用户分类

  • 学术研究所
  • 诊断实验室
  • 医院/诊所

第十章 南北美洲感染疾病体外诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太地区感染疾病体外诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东、非洲感染疾病体外诊断药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵,2023
  • 竞争情境分析
    • 罗氏推出下一代 QPCR 系统,以改善临床需求并应对分子诊断的公共卫生挑战
    • Biocare Medical 宣布推出新型 IVD 抗原修復室 ARC,用于可靠、准确且一致的热诱导表位修復 (HIER)
    • 推出免疫组织化学新试剂解决方案“Optimer-Fc”
    • DxLab 在烤麵包机大小的盒子中提供实验室品质的感染疾病和有害病原体检测

公司名单

  • Trinity Biotech PLC
  • Qiagen NV
  • DiaSorin SpA
  • Koninklijke Philips NV
  • Vela Diagnostics
  • InBios International, Inc.
  • PerkinElmer, Inc.
  • Quest Diagnostics
  • F. Hoffmann La-Roche Ltd.
  • bioMerieux SA
  • Laboratory Corporation Of America Holdings
  • Sysmex Corporation
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Grifols, SA
  • Hologic, Inc.
  • Siemens Healthineers AG
  • Danaher Corporation
  • Quidel Corporation
  • Epitope Diagnostics, Inc.
  • Genspeed Biotech GmbH
  • Meril Life Sciences Pvt. Ltd.
  • Abbott Laboratories
  • Uniogen Oy
  • DX Lab Inc.
  • Illumina, Inc.
  • OraSure Technologies, Inc.
  • Merck KGaA
  • Becton, Dickinson and Company
Product Code: MRR-A339DAEFAD44

The Infectious Diseases In-Vitro Diagnostics Market was valued at USD 49.06 billion in 2023, expected to reach USD 52.51 billion in 2024, and is projected to grow at a CAGR of 7.22%, to USD 79.95 billion by 2030.

The scope of the infectious diseases in-vitro diagnostics (IVD) market encompasses diagnostic tests performed on samples such as blood, tissue, and other body fluids to detect infectious diseases within the human body. This market has become essential due to rising global infectious disease prevalence, increasing demand for rapid diagnostic solutions, and the ongoing threat of pandemics like COVID-19. These diagnostics are imperative for timely and accurate diagnosis, facilitating proper treatment plans and management, thus saving lives and curbing disease spread. Key applications involve testing for diseases such as HIV, influenza, tuberculosis, hepatitis, and emerging infections, with end-use sectors including hospitals, clinical laboratories, and point-of-care settings. Market growth is significantly influenced by technological advancements like next-generation sequencing, PCR, and immunoassays leading to improved accuracy and speed. The novel use of AI and machine learning for interpreting diagnostic results also presents noteworthy opportunities. Furthermore, the growing emphasis on home testing, fueled by convenience, immediate result interpretation, and privacy, is carving a significant niche within this industry. However, challenges such as high costs of advanced diagnostics, regulatory hurdles, and limited healthcare infrastructure in developing regions restrain market expansion. Also, unreliable results due to technical limitations in specific tests can be a deterrent. A key area for innovation lies in the development of affordable, simple, yet highly sensitive portable diagnostics. These innovations can dramatically enhance accessibility, particularly in low-resource settings worldwide. Also, exploring biomarkers for novel diseases and expanding multiplex testing, which simultaneously targets multiple pathogens, can be game-changers. The nature of this market is highly dynamic, driven by the frequent emergence of new infectious threats, thus requiring continuous R&D investment and collaboration between technology providers and healthcare professionals to stay adept and responsive. Recommendations for capitalizing on market opportunities include strategic partnerships and robust investments in R&D to cultivate more effective, less expensive diagnostics.

KEY MARKET STATISTICS
Base Year [2023] USD 49.06 billion
Estimated Year [2024] USD 52.51 billion
Forecast Year [2030] USD 79.95 billion
CAGR (%) 7.22%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infectious Diseases In-Vitro Diagnostics Market

The Infectious Diseases In-Vitro Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Prevalence and Periodic Outbreak of Infectious Diseases
    • Rising Adoption of Rapid Test Kits for Diagnosis of Infectious Diseases
    • Implementation of Government Initiatives to Curb Viral Diseases
  • Market Restraints
    • Product Recalls of Infectious Disease In-vitro Diagnostics
  • Market Opportunities
    • Advancements in Genomics and Proteomics
    • Increasing Investments in R&D to Launch New IVD Products
  • Market Challenges
    • Limited Accessibility of Infectious Diseases In-vitro Diagnostics Kits

Porter's Five Forces: A Strategic Tool for Navigating the Infectious Diseases In-Vitro Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infectious Diseases In-Vitro Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infectious Diseases In-Vitro Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infectious Diseases In-Vitro Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infectious Diseases In-Vitro Diagnostics Market

A detailed market share analysis in the Infectious Diseases In-Vitro Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infectious Diseases In-Vitro Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infectious Diseases In-Vitro Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Infectious Diseases In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Trinity Biotech PLC, Qiagen N.V., DiaSorin S.p.A, Koninklijke Philips N.V., Vela Diagnostics, InBios International, Inc., PerkinElmer, Inc., Quest Diagnostics, F. Hoffmann La-Roche Ltd., bioMerieux SA, Laboratory Corporation Of America Holdings, Sysmex Corporation, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Grifols, S.A., Hologic, Inc., Siemens Healthineers AG, Danaher Corporation, Quidel Corporation, Epitope Diagnostics, Inc., Genspeed Biotech GmbH, Meril Life Sciences Pvt. Ltd., Abbott Laboratories, Uniogen Oy, DX Lab Inc., Illumina, Inc., OraSure Technologies, Inc., Merck KGaA, and Becton, Dickinson and Company.

Market Segmentation & Coverage

This research report categorizes the Infectious Diseases In-Vitro Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Instruments, Reagents, and Software.
  • Based on Technology, market is studied across Immunochemistry, Microbiology, and Molecular Diagnostics.
  • Based on Indication, market is studied across Candidiasis, Chlamydia, Clostridium difficile, CRE, Gastroenteritis, Gonorrhea, Hepatitis, HIV, HPV, MRSA, Respiratory Virus, Streptococcus, TB and Drug-resistant TB, and VRE.
  • Based on End-user, market is studied across Academic Research Institutes, Diagnostic Laboratories, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence and Periodic Outbreak of Infectious Diseases
      • 5.1.1.2. Rising Adoption of Rapid Test Kits for Diagnosis of Infectious Diseases
      • 5.1.1.3. Implementation of Government Initiatives to Curb Viral Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Product Recalls of Infectious Disease In-vitro Diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Genomics and Proteomics
      • 5.1.3.2. Increasing Investments in R&D to Launch New IVD Products
    • 5.1.4. Challenges
      • 5.1.4.1. Limited Accessibility of Infectious Diseases In-vitro Diagnostics Kits
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising demand for advanced reagents for testing infectious pathogens
    • 5.2.2. Technology: Expanding adoption of molecular diagnostics technology to quickly detect and quantify viral load, such as in HIV or hepatitis infections
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Infectious Diseases In-Vitro Diagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents
  • 6.4. Software

7. Infectious Diseases In-Vitro Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Immunochemistry
  • 7.3. Microbiology
  • 7.4. Molecular Diagnostics

8. Infectious Diseases In-Vitro Diagnostics Market, by Indication

  • 8.1. Introduction
  • 8.2. Candidiasis
  • 8.3. Chlamydia
  • 8.4. Clostridium difficile
  • 8.5. CRE
  • 8.6. Gastroenteritis
  • 8.7. Gonorrhea
  • 8.8. Hepatitis
  • 8.9. HIV
  • 8.10. HPV
  • 8.11. MRSA
  • 8.12. Respiratory Virus
  • 8.13. Streptococcus
  • 8.14. TB and Drug-resistant TB
  • 8.15. VRE

9. Infectious Diseases In-Vitro Diagnostics Market, by End-user

  • 9.1. Introduction
  • 9.2. Academic Research Institutes
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals & Clinics

10. Americas Infectious Diseases In-Vitro Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Infectious Diseases In-Vitro Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Infectious Diseases In-Vitro Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Roche Launches Next-Generation Qpcr System to Advance Clinical Needs In Molecular Diagnostics and Address Public Health Challenges
    • 13.3.2. Biocare Medical Announces the Launch of ARC: The New IVD Antigen Retrieval Chamber for Reliable, Precise and Consistent Heat Induced Epitope Retrieval (HIER)
    • 13.3.3. Launch of Optimer-Fc as a New Reagent Solution for Immunohistochemistry
    • 13.3.4. DxLab Delivers Lab-Quality Detection of Infectious Diseases and Harmful Pathogens in a Toaster-Size Box

Companies Mentioned

  • 1. Trinity Biotech PLC
  • 2. Qiagen N.V.
  • 3. DiaSorin S.p.A
  • 4. Koninklijke Philips N.V.
  • 5. Vela Diagnostics
  • 6. InBios International, Inc.
  • 7. PerkinElmer, Inc.
  • 8. Quest Diagnostics
  • 9. F. Hoffmann La-Roche Ltd.
  • 10. bioMerieux SA
  • 11. Laboratory Corporation Of America Holdings
  • 12. Sysmex Corporation
  • 13. Bio-Rad Laboratories, Inc.
  • 14. Thermo Fisher Scientific Inc.
  • 15. Grifols, S.A.
  • 16. Hologic, Inc.
  • 17. Siemens Healthineers AG
  • 18. Danaher Corporation
  • 19. Quidel Corporation
  • 20. Epitope Diagnostics, Inc.
  • 21. Genspeed Biotech GmbH
  • 22. Meril Life Sciences Pvt. Ltd.
  • 23. Abbott Laboratories
  • 24. Uniogen Oy
  • 25. DX Lab Inc.
  • 26. Illumina, Inc.
  • 27. OraSure Technologies, Inc.
  • 28. Merck KGaA
  • 29. Becton, Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CRE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GASTROENTERITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HPV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MRSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY RESPIRATORY VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STREPTOCOCCUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TB AND DRUG-RESISTANT TB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VRE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. NIGERIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. NIGERIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. NORWAY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. NORWAY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. POLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. POLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. SWEDEN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. SWEDEN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. SWITZERLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. SWITZERLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. TURKEY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. TURKEY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 203. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023